Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...
logo long.jpg
Chronic Pain Market to Surpass US$ 108,814 Million by 2028, Says Coherent Market Insights (CMI)
November 17, 2021 08:40 ET | CMI
SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic pain market is estimated to be valued at US$ 64,068 million in 2020 and is expected to exhibit a...
Axsome Logo.png
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
ibn-iw-globe-2.png
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 03, 2021 08:00 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
trypf.png
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
July 28, 2021 08:30 ET | Tryp Therapeutics Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
neurometrix_rgb.jpg
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
July 26, 2021 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on...
neurometrix_rgb.jpg
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
July 20, 2021 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKee
June 17, 2021 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- (via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Axsome Logo.png
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
June 15, 2021 07:00 ET | Axsome Therapeutics, Inc.
        Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the...